Monitor Corporation's 'Lucas Plus', selected as a new medical technology with deferred evaluation

Monitor Corporation , a medical AI specialized company, announced on the 21st that its AI lung cancer diagnosis solution 'LuCAS plus' was selected as a 'new medical technology with deferred evaluation' by the Korea Evidence-based Healthcare Collaborating Agency (NECA). With this, Monitor Corporation plans to take its activities one step further with the goal of more aggressive business expansion and increased market share in the medical market.

The 'Evaluation Deferral New Medical Technology' system is a system that postpones technology evaluation in order to promote the early introduction of new medical technologies, and technologies with recognized potential can be prescribed as non-covered medical treatments at domestic medical institutions. 'Lucas Plus' is a solution that automatically analyzes chest CT and supports diagnosis using AI, assisting medical staff in their final diagnosis and enabling efficient image interpretation. With this selection, 'Lucas Plus' can be prescribed as non-covered medical treatments at domestic medical institutions for up to five years starting in the second quarter of this year, and the number of hospitals introducing it is expected to increase rapidly.

'Lucas Plus' is the first class 3 medical device in Korea that can accurately detect lung cancer conditions, and has been selected as an innovative medical device by the Ministry of Food and Drug Safety. It is currently being used in over 100 medical institutions in Korea. In addition, through collaboration with Japanese digital healthcare company DoctorNet, full-scale sales activities are being carried out targeting Japanese medical institutions, and it is scheduled to be introduced to many Japanese medical institutions starting in April.

CEO Lee Kyung-joon said, “The fact that ‘Lucas Plus’ was selected as a new medical technology with deferred evaluation provides an opportunity for rapid introduction in the domestic medical field and the creation of abundant clinical evidence,” and added, “In the future, we will pursue formal health insurance listing through a new medical technology evaluation and strive to save more lives through medical innovation using AI.”

• See more related articles